Evidence map›Paper›PMID 36600184›Full record

ArticleStatistics in medicine2023

Covariate-specific evaluation of continuous biomarker.

Ziyi Li, Yijian Huang, Dattatraya Patil, Mark Rubin, Martin G Sanda

Abstract read
In one paragraph

Article in Statistics in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ziyi LiDepartment of Biostatistics, The University of Texas at MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-8359-0533
Yijian HuangDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia, USA.ORCID 0000-0003-4364-3199
Dattatraya PatilDepartment of Urology, Emory University, Atlanta, Georgia, USA.
Mark RubinDepartment for BioMedical Research, Bern Center for Precision Medicine, University of Bern, Bern, Switzerland.
Martin G SandaDepartment of Urology, Emory University, Atlanta, Georgia, USA.

Funding

Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas SouthwesternU01CA113913 · NCI · EMORY UNIVERSITY · PI Martin G. Sanda · 2005 to 2026
$16.4M
Statistical Methods for Cancer Detection Using BiomarkersR01CA230268 · NCI · EMORY UNIVERSITY · PI HUANG, YIJIAN · 2019 to 2023
$1.5M
Statistical models for intratumor heterogeneity of tumor-infiltrated leukocytes in lung cancerR03CA270725 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, ZIYI · 2022 to 2023
$162k
NCI NIH HHS R01 CA230268NCI NIH HHS R03 CA270725NCI NIH HHS U01 CA113913
6 · The paper itself

Abstract

Diagnostic tests usually need to operate at a high sensitivity or specificity level in practice. Accordingly, specificity at the controlled sensitivity, or vice versa, is a clinically sensible performance metric for evaluating continuous biomarkers. Meanwhile, the performance of a biomarker may vary across sub-populations as defined by covariates, and covariate-specific evaluation can be informative. In this article, we develop a novel modeling and estimation method for covariate-specific specificity at a controlled sensitivity level. Unlike existing methods which typically adopt elaborate models of covariate effects over the entire biomarker distribution, our approach models covariate effects locally at a specific sensitivity level of interest. We also extend our proposed model to handle the whole continuum of sensitivities via dynamic regression and derive covariate-specific ROC curves. We provide the variance estimation through bootstrapping. The asymptotic properties are established. We conduct extensive simulation studies to evaluate the performance of our proposed methods in comparison with existing methods, and further illustrate the applications in two clinical studies for aggressive prostate cancer.

Indexed as

Models, StatisticalProstatic NeoplasmsBiomarkersComputer SimulationHumansMaleROC CurveBiomarkerscontinuous biomarkerdynamic regressionlogistic regressionquantile regressionreceiver operating characteristic curvesensitivityspecificityspecificity at controlled sensitivity

Identifiers

PMID36600184
PMCPMC10071998

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.